Picture of Acadia Pharmaceuticals logo

ACAD Acadia Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual income statement for Acadia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue125224339442484
Cost of Revenue
Gross Profit112205319421466
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses417471586728655
Operating Profit-292-247-247-287-170
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-288-244-234-281-168
Provision for Income Taxes
Net Income After Taxes-221-245-235-282-168
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-289-245-235-282-168
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-289-245-235-282-168
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.8-1.94-1.6-1.79-1.05

Or unlock with your email

Or unlock with your email